Monocyte Trajectories Endotypes Are Associated With Worsening in Septic Patients.
ICU– Intensive Care Unit
endotype
flow cytometry
immune monitoring
immunosuppression
monocyte HLA-DR
sepsis
trajectory
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
14
10
2021
accepted:
11
11
2021
entrez:
16
12
2021
pubmed:
17
12
2021
medline:
5
3
2022
Statut:
epublish
Résumé
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. The immune system plays a key role in sepsis onset and remains dysregulated over time in a heterogeneous manner. Here, we decipher the heterogeneity of the first week evolution of the monocyte HLA-DR (mHLA-DR) surface protein expression in septic patients, a key molecule for adaptive immunity onset. We found and verified four distinctive trajectories endotypes in a discovery (n = 276) and a verification cohort (n = 102). We highlight that 59% of septic patients exhibit low or decreasing mHLA-DR expression while in others mHLA-DR expression increased. This study depicts the first week behavior of mHLA-DR over time after sepsis onset and shows that initial and third day mHLA-DR expression measurements is sufficient for an early risk stratification of sepsis patients. These patients might benefit from immunomodulatory treatment to improve outcomes. Going further, our study introduces a way of deciphering heterogeneity of immune system after sepsis onset which is a first step to reach a more comprehensive landscape of sepsis.
Identifiants
pubmed: 34912347
doi: 10.3389/fimmu.2021.795052
pmc: PMC8667763
doi:
Substances chimiques
Biomarkers
0
HLA-DR Antigens
0
Banques de données
ClinicalTrials.gov
['NCT02803346', 'NCT02638779']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
795052Informations de copyright
Copyright © 2021 Bodinier, Peronnet, Brengel-Pesce, Conti, Rimmelé, Textoris, Vedrine, Quemeneur, Griffiths, Tan, Venet, Maucort-Boulch and Monneret.
Déclaration de conflit d'intérêts
MB, JT, KB-P, and EP are employees of bioMérieux SA, an in vitro diagnostic company. FC, TR, FV, GM, and DM-B are employees of Hospices Civils de Lyon. MB, EP, KB-P, JT, TR, FC, and GM work in a joint research unit, co funded by the Hospices Civils de Lyon and bioMérieux. LT is employee of and holds stock and shares in GlaxoSmithKline. LQ is an employee of Sanofi Pasteur. CV is employee of BIOASTER. AG is employee of ESPCI Paris. The authors declare this study received funding from bioMérieux Sanofi and GSK. The funders were involved in the REALISM study design, collection, analysis, interpretation of data, writing of report, and decision to submit the article for publication.
Références
Crit Care. 2020 Mar 20;24(1):110
pubmed: 32192532
Cytometry B Clin Cytom. 2013 Jan-Feb;84(1):59-62
pubmed: 22987669
Intensive Care Med. 2015 Dec;41(12):2229-30
pubmed: 26359166
Cytometry B Clin Cytom. 2021 Jan;100(1):103-114
pubmed: 33432735
BMC Infect Dis. 2019 Nov 5;19(1):931
pubmed: 31690258
Lancet. 2008 Sep 20;372(9643):1107-19
pubmed: 18805339
BMJ Open. 2017 Jun 21;7(6):e015734
pubmed: 28637738
Am J Respir Crit Care Med. 2009 Oct 1;180(7):640-8
pubmed: 19590022
Crit Care Med. 2017 Dec;45(12):e1289-e1291
pubmed: 28991828
Lancet Respir Med. 2016 Apr;4(4):259-71
pubmed: 26917434
Crit Care. 2019 Mar 9;23(1):80
pubmed: 30850013
Lancet Respir Med. 2017 Oct;5(10):816-826
pubmed: 28864056
Am J Respir Crit Care Med. 2019 Apr 15;199(8):980-986
pubmed: 30365341
Crit Care. 2020 Apr 7;24(1):132
pubmed: 32264937
Nat Rev Nephrol. 2020 Jan;16(1):20-31
pubmed: 31511662
Biomed Res Int. 2016;2016:4213712
pubmed: 28050557
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Intensive Care Med. 2018 May;44(5):627-635
pubmed: 29915941
Intensive Care Med. 2010 Nov;36(11):1859-66
pubmed: 20652682
Intensive Care Med. 2006 Aug;32(8):1175-83
pubmed: 16741700
Crit Care Med. 2009 Oct;37(10):2746-52
pubmed: 19707128
JAMA. 2019 May 28;321(20):2003-2017
pubmed: 31104070
Crit Care. 2011;15(5):R220
pubmed: 21933399
Crit Care Med. 2021 Nov 10;:
pubmed: 34534131